Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P40225
UPID:
TPO_HUMAN
Alternative names:
C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; Myeloproliferative leukemia virus oncogene ligand
Alternative UPACC:
P40225; A1L3Y0; B7ZLR8; B9EGA8; Q13020; Q15790; Q15791; Q15792
Background:
Thrombopoietin, also known as the c-mpl ligand, plays a pivotal role in hematopoiesis by regulating the proliferation and maturation of megakaryocytes, leading to platelet formation. It is recognized as the primary physiological regulator of circulating platelets, acting at a late stage of megakaryocyte development.
Therapeutic significance:
Thrombocythemia 1, a myeloproliferative disorder characterized by excessive platelet production, is directly linked to variants affecting the gene encoding Thrombopoietin. This connection underscores the protein's potential as a target for therapeutic intervention in managing thrombotic episodes and spontaneous hemorrhages associated with the disease.